Latest Corporate News
US CEOs Rank Economic Uncertainty as Top 2026 Threat
43% of U.S. CEOs cite economic uncertainty as their primary concern for 2026, surpassing recession fears, per Conference Board survey of 1,700 executives. Cyberattacks top geopolitical risks at 54% for U.S. leaders versus 47% globally.
AI ROI measurement is the key focus, with 46% aiming to enhance data quality.
Dealmakers Predict Retail Merger and IPO Surge in 2026
Retail M&A and IPOs expected to rise after tariffs stalled deals last year, with chains like restaurant groups and Once Upon a Farm primed. Mega deals like Kimberly-Clark's $50B Kenvue acquisition marked late-year resurgence.
Splits like Kraft Heinz and private equity carveouts signal growth focus.
Playlist Merges with EGYM in $7.5B Fitness Tech Deal
Vista's Playlist (Mindbody, Booker, ClassPass) to merge with EGYM, valuing combined firm at $7.5B with $785M new equity. Announced January 15, 2026, pending regulatory approvals.
Targets smart fitness, AI workouts, and wellness solutions.
Compass Acquires Anywhere Real Estate for $1.6B
Compass becomes world's largest brokerage via all-stock $1.6B deal, adding Corcoran, Sotheby's, Coldwell Banker brands. Controls 40% of NY/SF sales volume, 20% nationally with 340,000 agents.
Fast-tracked despite antitrust concerns, completed early January.
Netflix Acquires Warner Bros. in Major Media Merger
Netflix buys Warner Bros., spinning off CNN, Discovery, TNT, TBS as worthless Discovery Global amid wave of media consolidations. Follows Paramount-Skydance $6.6B deal and prior AT&T Time Warner spins.
Highlights $108B to $0 value erosion in legacy assets.
Worthington Steel to Buy Germany's Klöckner & Co for $2.4B
US-based Worthington Steel announces acquisition of steel distributor Klöckner & Co, expected to close H2 2026. Strengthens global steel supply chain presence.
Deal values target at $2.4 billion.
AbbVie, Novartis Strike Billion-Dollar Biopharma Pacts
AbbVie and Novartis announce major deals at J.P. Morgan Healthcare Conference amid M&A anticipation. Merck eyes multi-tens-of-billions acquisitions.
Includes Lilly's Ventyx buy and others expanding portfolios.
ESTEVE Acquires TerSera's Infusion Therapies Unit
ESTEVE expands U.S. presence by buying TerSera Therapeutics’ infusion specialty business. Part of January 2026 biopharma M&A wave.
Bolsters therapeutic offerings.
Bayer Enters Molecular Imaging via Attralus Acquisition
Bayer acquires innovative Pan-Amyloid radiotracers from Attralus to grow in molecular imaging. Announced January 12, 2026.
Targets amyloid-related diagnostics.
Lilly Acquires Ventyx Biosciences for Inflammatory Therapies
Eli Lilly buys Ventyx to advance oral treatments for inflammatory diseases. Deal announced January 8, 2026.
Enhances pipeline in immunology.
CCL Industries to Acquire ALT in Packaging Deal
CCL Industries signs agreement for ALT acquisition, closing Q2 2026 pending approvals. President Geoffrey T. Martin oversees strategic expansion.
Focuses on packaging sector growth.